Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections
CA 2708703 C · Owner: Salus Pharma, Inc. · Inventors: Montgomery, Alan Bruce
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli Klebsiella pneumoniae, Klebsiella oxytoca Pseudomonas aeruginosa, Haemophilus influenzae Proteus mirabilis, Enterobacter species Serratia marcescens as well as those caused by Burkholderia cepacia Stenotrophomonas maltophilia, Alcaligenes xylosoxidans and multidrug reistant Pseudomonas aeruginosa using a concentrated formulation of aztreozonam or a pharmaceutically acceptable salt thereof delivered as an aerosol or dry powder formulation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 20, 2001 and granted December 4, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 20, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 20, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.